Literature DB >> 24629527

Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer?

Weihong Ding1, Zhongqing Chen2, Yuancheng Gou1, Chuanyu Sun1, Ke Xu3, Jun Tan4, Shijun Tong1, Guowei Xia1, Qiang Ding1.   

Abstract

OBJECTIVE: To evaluate the applicability of using EORTC risk tables in Chinese patients with non-muscle-invasive bladder cancer.
MATERIAL AND METHODS: Between October 2000 and July 2009, 301 patients with NMIBC who underwent transurethral resection of the bladder tumor (TURBT) at our hospital were followed up. The probability of recurrence and progression at 1 year and 5 years post-operatively was calculated along with the 95% confidence intervals. We then compared the actual probabilities in our center to those obtained through the application of the EORTC risk tables.
RESULTS: Median patient age was 67 years (range, 21-92 years), and the median follow-up duration was 46 months (range, 2-151 months). The probability of recurrence at 1 year ranged from 2% to 58%, and the probability of progression ranged from less than 1.2% to 30%. At 5 years, the probability of recurrence ranged from 12% to 85%, and the probability of progression ranged from less than 2.9% to 50%. An overlapping of the confidence intervals of the probability between our series and the EORTC group is detected.
CONCLUSIONS: Although the immediate instillation of intravesical chemotherapy may reduce the risk of recurrence, EORTC risk tables could predict recurrence and progression in Chinese patients with non-muscle-invasive bladder cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Non-muscle-invasive bladder cancer; Prognostic factors; Progression; Recurrence

Mesh:

Year:  2014        PMID: 24629527     DOI: 10.1016/j.canep.2014.02.001

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  5 in total

1.  Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups.

Authors:  Weihong Ding; Shijun Tong; Yuancheng Gou; Chuanyu Sun; Hong Wang; Zhongqing Chen; Jun Tan; Ke Xu; Guowei Xia; Qiang Ding
Journal:  World J Urol       Date:  2015-04-18       Impact factor: 4.226

2.  The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBt) in Chinese population.

Authors:  Shenghua Liu; Junyao Hou; Hu Zhang; Yishuo Wu; Mengbo Hu; Limin Zhang; Jianfeng Xu; Rong Na; Haowen Jiang; Qiang Ding
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

Review 3.  A review on the accuracy of bladder cancer detection methods.

Authors:  Chao-Zhe Zhu; Hua-Nong Ting; Kwan-Hoong Ng; Teng-Aik Ong
Journal:  J Cancer       Date:  2019-07-08       Impact factor: 4.207

4.  External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.

Authors:  Gilberto L Almeida; Wilson F S Busato; Carmen Marcondes Ribas; Jurandir Marcondes Ribas; Ottavio De Cobelli
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

5.  EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.

Authors:  Hui Wang; Weihong Ding; Guangliang Jiang; Yuancheng Gou; Chuanyu Sun; Zhongqing Chen; Ke Xu; Guowei Xia
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.